Cart
sales@molnova.com
JNJ-1661010
CAS No. 681136-29-8
JNJ-1661010( JNJ-1661010 | JNJ 1661010 | JNJ1661010 )
Catalog No. M18990 CAS No. 681136-29-8
JNJ-1661010 is an effective and specific FAAH inhibitor (IC50: 10/ 12 nM for rat/human), shows >100-fold selectivity for FAAH-1 than FAAH-2.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 35 | In Stock |
|
| 10MG | 60 | In Stock |
|
| 25MG | 129 | In Stock |
|
| 50MG | 205 | In Stock |
|
| 100MG | 331 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameJNJ-1661010
-
NoteResearch use only, not for human use.
-
Brief DescriptionJNJ-1661010 is an effective and specific FAAH inhibitor (IC50: 10/ 12 nM for rat/human), shows >100-fold selectivity for FAAH-1 than FAAH-2.
-
DescriptionJNJ-1661010 is a selective, reversible inhibitor of fatty acid amide hydrolase (FAAH) (IC50 = 12 nM). JNJ-1661010 is a brain penetrant and active in vivo.
-
In Vitro——
-
In VivoJNJ-1661010 (Takeda-25; i.p.; 50 mg/kg) diminishes thermal hyperalgesia in the inflammatory rat carrageenan paw model. JNJ-1661010 (i.p.; 10 mg/kg) has a T1/2 of 35 mins, a CL of 0.032 mL/min/kg, and a Cmax of 1.58 μM for rats.
-
SynonymsJNJ-1661010 | JNJ 1661010 | JNJ1661010
-
PathwayOthers
-
TargetOther Targets
-
RecptorFAAH (human)| FAAH (rat)
-
Research AreaOthers-Field
-
Indication——
Chemical Information
-
CAS Number681136-29-8
-
Formula Weight365.45
-
Molecular FormulaC19H19N5OS
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (273.64 mM)
-
SMILESO=C(Nc1ccccc1)N1CCN(CC1)c1nc(ns1)c1ccccc1
-
Chemical Name1-Piperazinecarboxamide, N-phenyl-4-(3-phenyl-1,2,4-thiadiazol-5-yl)-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Karbarz MJ, et al. Anesth Analg, 2009, 108(1), 316-329.
molnova catalog
related products
-
Azide-PEG12-Tos
Azide-PEG12-Tos is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
-
Siplizumab
Siplizumab (MEDI-507) is a humanized IgG1 monoclonal antibody that targets CD2, selectively depleting effector memory T cells and promoting the relative expansion of alloreactive regulatory T cells in vitro. Siplizumab can be used to treat plaque psoriasis.
-
Desoxo-narchinol A
Desoxo-narchinol A exhibits protective effects against LPS-induced endotoxin shock and inflammation through p38 deactivation, it shows inhibitory activity against LPS-induced NO production. Desoxo-narchinol A shows cytotoxic activity against P-388 cells.
